Nuveen LLC Invests $2.70 Million in Quanterix Corporation $QTRX

Key Points

• Nuveen LLC has acquired a new stake in Quanterix Corporation, purchasing 415,378 shares valued at approximately $2.7 million, representing 1.07% of the company's stock.
• Quanterix recently posted earnings showing a loss of ($0.47) per share, which was below analysts' expectations, and reported revenue of $24.48 million for the quarter.
• Institutional investors collectively own 86.48% of Quanterix Corporation's stock, with several firms increasing their stakes significantly in the first quarter.

Nuveen LLC acquired a new stake in shares of Quanterix Corporation (NASDAQ:QTRX - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 415,378 shares of the company's stock, valued at approximately $2,704,000. Nuveen LLC owned 1.07% of Quanterix as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC bought a new position in Quanterix in the first quarter valued at approximately $98,000. Two Sigma Investments LP bought a new position in Quanterix in the fourth quarter valued at approximately $606,000. Price T Rowe Associates Inc. MD lifted its stake in Quanterix by 18.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 33,878 shares of the company's stock valued at $361,000 after buying an additional 5,385 shares in the last quarter. Raymond James Financial Inc. bought a new position in Quanterix in the fourth quarter valued at approximately $570,000. Finally, Jane Street Group LLC lifted its stake in Quanterix by 18.1% in the fourth quarter. Jane Street Group LLC now owns 55,947 shares of the company's stock valued at $595,000 after buying an additional 8,578 shares in the last quarter. Institutional investors and hedge funds own 86.48% of the company's stock.

Insider Activity

In other Quanterix news, Director William P. Donnelly purchased 93,113 shares of the firm's stock in a transaction that occurred on Friday, June 6th. The shares were acquired at an average cost of $5.44 per share, for a total transaction of $506,534.72. Following the completion of the purchase, the director owned 139,094 shares of the company's stock, valued at approximately $756,671.36. The trade was a 202.50% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David R. Walt purchased 131,869 shares of the firm's stock in a transaction that occurred on Friday, June 6th. The stock was acquired at an average price of $5.43 per share, for a total transaction of $716,048.67. Following the completion of the purchase, the director directly owned 1,628,802 shares of the company's stock, valued at $8,844,394.86. This represents a 8.81% increase in their position. The disclosure for this purchase can be found here. Insiders purchased 463,113 shares of company stock worth $2,625,444 over the last 90 days. 6.90% of the stock is currently owned by corporate insiders.

Quanterix Stock Up 0.2%

Shares of QTRX stock traded up $0.01 during trading on Friday, reaching $4.55. The company's stock had a trading volume of 481,164 shares, compared to its average volume of 815,728. The business has a fifty day moving average price of $5.62 and a 200-day moving average price of $5.95. Quanterix Corporation has a one year low of $4.05 and a one year high of $15.85. The company has a market cap of $211.42 million, a price-to-earnings ratio of -2.50 and a beta of 1.07.

Quanterix (NASDAQ:QTRX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.06). Quanterix had a negative return on equity of 18.41% and a negative net margin of 56.04%.The firm had revenue of $24.48 million for the quarter, compared to the consensus estimate of $29.73 million. Quanterix has set its FY 2025 guidance at EPS. Research analysts anticipate that Quanterix Corporation will post -0.98 EPS for the current year.

Analyst Upgrades and Downgrades

QTRX has been the topic of a number of research reports. Wall Street Zen lowered shares of Quanterix from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Canaccord Genuity Group reaffirmed a "hold" rating and issued a $5.00 price target (down previously from $12.00) on shares of Quanterix in a research note on Monday, August 11th. One analyst has rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $11.75.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.